Price Chart

Profile

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
URL https://www.algernonpharmaceuticals.com
Investor Relations URL N/A
HQ State/Province British Columbia
Sector  
Industry  
Equity Style Small Cap/Value
Next Earnings Release Jan. 24, 2025 (est.)
Last Earnings Release Jul. 30, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
URL https://www.algernonpharmaceuticals.com
Investor Relations URL N/A
HQ State/Province British Columbia
Sector  
Industry  
Equity Style Small Cap/Value
Next Earnings Release Jan. 24, 2025 (est.)
Last Earnings Release Jul. 30, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A